A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
Recruiting · Phase 2 · NCT07116031
Conditions: Chronic Graft Versus Host Disease
At a glance
- Research payments reported, 2025
- $27,392
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 37
About the trial
- Sponsor
- Sanofi (with Meiji Seika Pharma Co., Ltd.)
- Tested
- Belumosudil (drug), Belumosudil (drug)
- Dates
- Started 2025-12-02; completion 2031-02-28
- Results posted
- Not yet
This is an open-label, single group, Phase 1/2, 1-arm study for treatment of children aged 1 to \<18 years with active moderate-to-severe cGVHD that is refractory to or recurred after at least 2 prior lines of systemic therapy for cGVHD. The purpose of Phase 1 is to determine the PK profiles and to establish the Recommended Pediatric Equivalent Dose (RPED) of belumosudil in participants aged 1 to \<12 years with active moderate to severe cGVHD. Upon completion and evaluation of Phase 1, Phase 2 will commence with the purpose of determining safety and efficacy (ORR by 24 weeks) of belumosudil in participants aged 1 to \<18 years. Study details include: The end of study is defined as 3 year…
From ClinicalTrials.gov, last updated 2026-09-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $27,392 in research payments for this study in 2025 (1 payments).
Products named: Rezurock
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan Kettering Cancer Center $27,392
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.